Pharmaceuticals

Drug Development Drug Pricing Drug Safety Drug Approval Weight Loss Drugs Prescription Drugs Clinical Trials Drug Manufacturing Drug Regulation Prescription Medications

4 ARTICLES

3d ago

White House Secures Deals With Nine More Drugmakers, Bringing Price‑Cut Pact to 14 of 17 Targets

In exchange for three years of tariff relief, companies commit to MFN Medicaid pricing, deep TrumpRx.gov cash discounts and a pledged $150 billion in U.S. investment.

77 ARTICLES

4d ago

Trump Adds Nine Pharma Giants to Drug Pricing Deals, Reaching 14 Signatories as TrumpRx Nears Launch

8 ARTICLES

5d ago

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

3 ARTICLES

5d ago

JPMorgan Upgrades Recursion, Raises Target to $11 as Shares Surge on AI Drug Signals

7 ARTICLES

last wk.

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

3 ARTICLES

last wk.

FDA Grants Fast Track to Palvella’s QTORIN Rapamycin for Angiokeratomas

3 ARTICLES

last wk.

SK Capital Affiliate to Invest in Swixx BioPharma at Valuation Above €1.5 Billion

8 ARTICLES

last wk.

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

6 ARTICLES

last wk.

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

6 ARTICLES

last wk.

Ontario ADHD Stimulant Prescriptions Jump 157% Since 2015, With Fastest Growth in Adult Women

4 ARTICLES

last wk.

FDA Panel Urges Looser Testosterone Rules, Including Descheduling and Broader Use

4 ARTICLES

last wk.

HSBC Upgrades AbbVie to Buy, Lifts Target to $265 as Skyrizi and Rinvoq Drive Growth

3 ARTICLES

last wk.

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

4 ARTICLES

last wk.

Daré Bioscience Launches Topical Sildenafil Cream for Female Arousal

3 ARTICLES

last wk.

Yahoo Finance Highlights Merck and Bristol Myers as Value Plays Outside the GLP-1 Surge

10 ARTICLES

last wk.

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

3 ARTICLES

last wk.

Formycon, Zydus Seal Exclusive Deal for Keytruda Biosimilar in U.S. and Canada

5 ARTICLES

2w ago

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

3 ARTICLES

2w ago

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

4 ARTICLES

2w ago

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Pharmaceuticals

White House Secures Deals With Nine More Drugmakers, Bringing Price‑Cut Pact to 14 of 17 Targets

Trump Adds Nine Pharma Giants to Drug Pricing Deals, Reaching 14 Signatories as TrumpRx Nears Launch

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

JPMorgan Upgrades Recursion, Raises Target to $11 as Shares Surge on AI Drug Signals

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

FDA Grants Fast Track to Palvella’s QTORIN Rapamycin for Angiokeratomas

SK Capital Affiliate to Invest in Swixx BioPharma at Valuation Above €1.5 Billion

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

Ontario ADHD Stimulant Prescriptions Jump 157% Since 2015, With Fastest Growth in Adult Women

Never miss stories about

Pharmaceuticals

FDA Panel Urges Looser Testosterone Rules, Including Descheduling and Broader Use

HSBC Upgrades AbbVie to Buy, Lifts Target to $265 as Skyrizi and Rinvoq Drive Growth

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

Daré Bioscience Launches Topical Sildenafil Cream for Female Arousal

Yahoo Finance Highlights Merck and Bristol Myers as Value Plays Outside the GLP-1 Surge

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

Formycon, Zydus Seal Exclusive Deal for Keytruda Biosimilar in U.S. and Canada

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Never miss stories about

Pharmaceuticals